| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | bezuclastinib combination Gastrointestinal Stromal Tumors (GIST) in patients who previously received imatinib Breakthrough | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology | |
PDUFA Date example | bezuclastinib combination Gastrointestinal Stromal Tumors (GIST) in patients who previously received imatinib Breakthrough | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology | |
PDUFA Date example | bezuclastinib combination Gastrointestinal Stromal Tumors (GIST) in patients who previously received imatinib Breakthrough | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Cogent Biosciences, Inc.
$36.23
-0.5 (-1.36%)
C 49Pipeline Score Richly Valued Biotech · Clinical
Market Cap
6.29 B
EPS
-2.17
P/E Ratio
-
Value Trade
66.66 M
-3.13 %
Week
-10.41 %
1 Month
6.75 %
3 Month
-7.53 %
6 Month
281.66 %
5 Year
-30.49 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.21 M
52 Week Range
11.60 - 43.73
% held by Insiders
10.38 %
% held by Institutions
103.12 %
Enterprise Value
5.72 B
Total Shares
173.52 M
Short %
11.5 %
Float Shares
137.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cogent Biosciences, Inc.
380Total events
10Upcoming
74Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 2
TBD
T1PDUFA Date
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
●ATM ProgramCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | Bezuclastinib | NDA Filing | NDA | — | – | – | – |
2026-06-30 | Bezuclastinib | NDA Filing | NDA | — | – | – | – |
2026-06-30 | Bezuclastinib | NDA Filing | NDA | — | – | – | – |
Drug Pipeline Intelligence
C49
Pipeline Score $709M
Pipeline ValueRichly Valued
Valuation Signal6
Drugs Scored0.1x
rNPV / MCap Top 80%
Small Cap (rank 188 of 933)
Percentile RankCogent Biosciences, Inc. carries a moderate pipeline score (49/100), with $1.1B risk-adjusted pipeline value, led by Bezuclastinib in SSM (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bezuclastinib Small molecule | SSM | Phase 2 | NCT05186753 | 71% | $324M | ACTIVE NOT_RECRUITING | 237 | AVERAGE | B (72) | Apr 1, 2030 | ELEVATED_RISK | May 22, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
bezuclastinib BreakthroughPriority | advanced systemic mastocytosis | — | 2026-06-12 | 65% objective response rate; 81% ORR per PPR criteria; 91% of patients achieving ≥50% reduction in variant allele frequency; 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates; 12-month PFS rate of 79%; 12-month OS rate of 87% Read More | Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress Read More | |
bezuclastinib BreakthroughPriority | advanced systemic mastocytosis | — | 2026-06-12 | 65% objective response rate; 81% ORR per PPR criteria; 91% of patients achieving ≥50% reduction in variant allele frequency; 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates; 12-month PFS rate of 79%; 12-month OS rate of 87% Read More | Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress Read More | |
bezuclastinib BreakthroughPriority | advanced systemic mastocytosis | — | 2026-06-12 | 65% objective response rate; 81% ORR per PPR criteria; 91% of patients achieving ≥50% reduction in variant allele frequency; 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates; 12-month PFS rate of 79%; 12-month OS rate of 87% Read More | Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COGT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COGT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COGTCogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences reported positive developments including the potential FDA approval of bezuclastinib for GIST and NonAdvSM patients by the end of 2026. The company has successfully onboarded a skilled customer-facing team and maintains a robust cash position to support operations. However, it also reported a significant net loss and rising R&D expenses.
Read more →COGTCogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences has submitted a New Drug Application for bezuclastinib to the FDA for treating Advanced Systemic Mastocytosis. The submission is based on positive results from the APEX pivotal trial, which demonstrated a 65% objective response rate and a well-tolerated safety profile. The company is optimistic about achieving FDA approval by Q4 2026.
Read more →COGTCogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences presented promising preclinical data for its JAK2 V617F inhibitor, CGT1145, at the 2026 EHA Congress. The drug exhibits high selectivity and oral bioavailability, potentially addressing key disease drivers in myeloproliferative neoplasms. The company aims to submit an Investigational New Drug application in 2026.
Read more →COGTCogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences presented updated results from the APEX trial of bezuclastinib for advanced systemic mastocytosis at the 2026 EHA Congress. The trial demonstrated a 65% objective response rate and significant reductions in mast cell burden. The drug also showed a favorable safety profile. An NDA submission is planned for June 2026.
Read more →COGTCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences announced promising results from the PEAK Phase 3 trial, demonstrating that the bezuclastinib and sunitinib combination significantly improves progression-free survival in GIST patients compared to sunitinib alone. The combination therapy was well tolerated, with no new risks identified. The FDA has granted Priority Review for this treatment, with a PDUFA date set for November 30, 2026.
Read more →COGTCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
Cogent Biosciences has announced the FDA's acceptance of its New Drug Application for bezuclastinib in combination with sunitinib for treating GIST patients. The application has been granted Priority Review, with a target action date set for November 30, 2026. The combination therapy demonstrated a significant improvement in median progression-free survival compared to sunitinib alone, marking a potential breakthrough in treatment options.
Read more →COGTCogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
Cogent Biosciences, Inc. will participate in the Jefferies Global Healthcare Conference on June 3, 2026. The event will feature a live webcast accessible via the company's website. Additionally, Cogent announced inducement equity awards for new employees, reflecting its commitment to growth and innovation in precision therapies for genetically defined diseases.
Read more →COGTCogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Cogent Biosciences has announced two key presentations at the upcoming European Hematology Association Congress 2026. The company will present pivotal data from its APEX trial on bezuclastinib, a therapy for Advanced Systemic Mastocytosis, showcasing its findings in two oral sessions. Additionally, preclinical data from their selective JAK2 V617F program will be highlighted in a poster presentation. These presentations represent a significant platform for Cogent to share its advancements in targeted therapies at an esteemed international venue.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal d
Cogent Biosciences has reported significant business highlights and financial results for Q1 2026, including plans for dual launches of their drug bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors. The company has a strong financial position, ending the quarter with $866.4 million in cash, which is expected to fund operations into 2028. The upcoming ASCO annual meeting will feature pivotal data from the Phase 3 PEAK trial, potentially setting the stage for multiple drug launches. However, the company recorded a larger net loss this quarter compared to the previous year, alongside increased R&D expenses.
Read more →COGTCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences announced that results from its Phase 3 PEAK trial will be presented at the 2026 ASCO Annual Meeting. The trial demonstrated positive outcomes for bezuclastinib combined with sunitinib in GIST patients previously treated with imatinib. The company is also set to initiate a Phase 2 trial for first-line GIST patients with exon 9 mutations.
Read more →COGTCogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Cogent Biosciences announced the presentation of preclinical data on its KRAS and ErbB2 pipeline programs at the AACR Annual Meeting 2026. The data highlights CGT1263's selectivity and potential to reduce skin toxicity, while CGT4255 shows promise in combination with HER2 ADCs for resistant patients. The company is preparing for the potential launch of bezuclastinib later this year.
Read more →COGT▼ -8.4%on this news
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences has submitted a New Drug Application for bezuclastinib to the FDA for treating gastrointestinal stromal tumors (GIST) in patients previously treated with imatinib. The submission is based on positive results from the Phase 3 PEAK trial, which showed a significant increase in progression-free survival and response rates compared to existing treatments. The company aims to present full trial results at a major medical meeting in 2026.
Read more →COGTCogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences has announced the FDA's acceptance of its New Drug Application for bezuclastinib, targeting patients with NonAdvanced Systemic Mastocytosis. The FDA set a target action date of December 30, 2026, and plans to avoid an advisory committee meeting. Clinical trial results indicated significant improvements across primary and secondary endpoints, showcasing bezuclastinib's efficacy and safety profile. The company is also on track to submit additional NDA applications for bezuclastinib in related indications in the near future.
Read more →COGTCogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
Cogent Biosciences presented additional data from the SUMMIT trial at the AAAAI Annual Meeting, highlighting the efficacy of bezuclastinib in treating NonAdvanced Systemic Mastocytosis. The results showed significant improvements across primary and secondary endpoints, reinforcing the drug's potential as a preferred treatment option. The findings also indicated benefits in bone mineral density, suggesting disease modification.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences reported strong business highlights and financial results for 2025, showcasing momentum with three successful pivotal trials. The company is advancing its lead product, bezuclastinib, with multiple NDA submissions planned for 2026. Despite a net loss of $102.5 million in Q4 2025, Cogent maintains a robust cash position of $900.8 million.
Read more →COGTCogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
Cogent Biosciences announced that it will present multiple posters at the 2026 AAAAI Annual Meeting, focusing on bezuclastinib results from the SUMMIT trial in patients with NonAdvanced Systemic Mastocytosis. The company has submitted a New Drug Application for bezuclastinib based on positive clinical data and previously received Breakthrough Therapy Designation. The presentations will take place on February 28, 2026.
Read more →COGTCogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences has received Breakthrough Therapy Designation from the FDA for bezuclastinib combined with sunitinib for treating imatinib-resistant GIST. The designation is based on promising results from the PEAK trial, showing a 50% reduction in disease progression risk. Cogent plans to submit its NDA by April 2026 and present full trial results at a major medical meeting.
Read more →COGTCogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences has received Breakthrough Therapy Designation from the FDA for its drug bezuclastinib in combination with sunitinib for treating gastrointestinal stromal tumors (GIST) in patients resistant to imatinib. The designation is based on promising results from the PEAK trial, showing a 50% reduction in disease progression risk. The company plans to submit its New Drug Application by April 2026 and present full trial results at a major medical meeting.
Read more →COGTCogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
Cogent Biosciences has announced the initiation of a New Drug Application (NDA) for bezuclastinib under the FDA's Real-Time Oncology Review program. The NDA is based on positive results from the PEAK trial, which demonstrated significant clinical benefits for patients with imatinib-resistant Gastrointestinal Stromal Tumors (GIST). Completion of the NDA submission is expected by April 2026, with plans for further clinical trials.
Read more →COGTCogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
Cogent Biosciences has outlined key milestones for 2026, which include multiple NDA submissions for bezuclastinib targeting NonAdvanced Systemic Mastocytosis, Advanced Gastrointestinal Stromal Tumors, and Advanced Systemic Mastocytosis. The company plans to commercially launch bezuclastinib in the second half of 2026, contingent upon FDA approval. Additionally, Cogent will present clinical data from pivotal trials during major medical meetings and has secured a solid financial position with approximately $900 million in cash. The organization is also strengthening its team with new leadership in sales to support its commercial endeavors.
Read more →COGTCogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Cogent Biosciences, Inc. has announced that CEO Andrew Robbins will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. The company specializes in precision therapies for genetically defined diseases. They are known for their clinical program involving bezuclastinib, targeting mutations associated with systemic mastocytosis and gastrointestinal stromal tumors. A live webcast of the presentation will be available, with a replay accessible afterwards.
Read more →COGTCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Cogent Biosciences has submitted a New Drug Application (NDA) for bezuclastinib for NonAdvanced Systemic Mastocytosis to the FDA. This submission is based on positive results from the SUMMIT trial, which showed significant improvements in patient symptoms. The company plans two additional NDA submissions for other indications in 2026, reflecting its commitment to addressing unmet medical needs.
Read more →COGTCogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
Cogent Biosciences presented full results from the SUMMIT trial of bezuclastinib in patients with nonadvanced systemic mastocytosis. The trial showed significant improvements in symptoms and disease markers, with a favorable safety profile. The company plans to submit a New Drug Application to the FDA in December 2025, with ongoing interest in their Expanded Access Program.
Read more →COGTCogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences announced positive top-line results from the APEX Part 2 trial of bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The trial demonstrated a 57% objective response rate, with 89% of patients experiencing at least a 50% reduction in bone marrow mast cells. Bezuclastinib exhibited strong safety and tolerability, with only a small percentage requiring dose adjustments. The company plans to submit a new drug application to the FDA in the first half of 2026, preparing for multiple commercial launches later that year.
Read more →COGTCogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
Cogent Biosciences, Inc. has announced its participation in the Jefferies Global Healthcare Conference, scheduled for November 19, 2025. This event will take place in London and offers a live webcast for interested investors. The company is renowned for its focus on developing precision therapies for genetically defined diseases, including ongoing clinical studies for bezuclastinib and other innovative treatments. The participation in this prominent conference may enhance the company's profile among investors and industry stakeholders.
Read more →COGT▲ +5.5%on this newsshared move
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
Cogent Biosciences has priced its public offerings, raising around $475.3 million. The offerings include 9.7 million shares of common stock priced at $31 each and $200 million in convertible senior notes due 2031. The funds will be used for loan repayments and to advance development activities for bezuclastinib and other candidates.
Read more →COGT▲ +119%on this newsshared move
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences announced positive results from its Phase 3 PEAK trial, showing that the combination of bezuclastinib and sunitinib significantly improves median progression-free survival in patients with imatinib-resistant or intolerant gastrointestinal stromal tumors (GIST). The trial reported a median PFS of 16.5 months compared to 9.2 months for sunitinib alone. The objective response rate was also notably higher at 46%. Cogent plans to submit a new drug application to the FDA in the first half of 2026.
Read more →COGT▲ +119%on this newsshared move
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
Cogent Biosciences announced its intention to conduct public offerings of $200 million in convertible senior notes due 2031 and $200 million in common stock. The company aims to use the proceeds to repay existing loans and support the development and commercialization of its product candidates, particularly bezuclastinib. The offerings are not interdependent, and completion relies on market conditions. The transaction is being managed by multiple financial institutions, and precise terms will be detailed in future prospectus supplements.
Read more →COGT▲ +119%on this newsshared move
Peak Trial: Bezuclastinib + Sunitinib in Gastrointestinal Stromal Tumors (GIST) Top-Line Results Investor Webcast
Cogent Biosciences presented promising top-line results for its trial of Bezuclastinib in combination with Sunitinib for treating gastrointestinal stromal tumors (GIST). The combination therapy addresses significant unmet needs for patients with imatinib-resistant or intolerant GIST, targeting a wide range of mutations causing the disease. Key endpoints such as progression-free survival (PFS) will be further investigated, with complete results expected to be disclosed at an upcoming medical meeting. This trial highlights potential advancements in treatment options for patients with this challenging cancer type.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
Cogent Biosciences reported significant progress in its clinical trials and financial results for Q3 2025. The company anticipates key results from its Phase 3 PEAK trial in GIST patients and the APEX trial in AdvSM patients in the coming months. With a strong cash position of $430 million, Cogent is well-positioned for upcoming milestones, including an NDA filing for bezuclastinib by year-end 2025.
Read more →COGTCogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
Cogent Biosciences announced multiple presentations at the 67th ASH Meeting, focusing on bezuclastinib's promising results in NonAdvanced Systemic Mastocytosis. Two oral presentations will detail efficacy and safety data from the SUMMIT trial. Additionally, the company will introduce a novel JAK2 V617F mutant-selective inhibitor, expected to be submitted for IND in 2026.
Read more →COGTCogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Cogent Biosciences has announced updated preclinical data for its pan KRAS(ON) inhibitor, CGT1263, at the 2025 AACR-NCI-EORTC Conference. The data suggest a promising profile for CGT1263, which shows selectivity for mutant KRAS over other RAS proteins. The company aims to file an IND application with the FDA in 2026.
Read more →COGTCogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
Cogent Biosciences has received FDA Breakthrough Therapy Designation for bezuclastinib, aimed at treating NonAdvanced Systemic Mastocytosis. This designation underscores the unmet medical need in this patient population. The company plans to submit a New Drug Application (NDA) by the end of 2025, following positive results from the SUMMIT trial. Additional pivotal trial results are expected in the coming months.
Read more →COGTCogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cogent Biosciences has announced the approval of inducement equity awards for 10 new employees under its 2020 Inducement Plan. The awards, totaling options for 299,200 shares, were granted by the independent Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4). Each option has a 10-year term and a four-year vesting schedule.
Read more →COGTCogent Biosciences Announces Participation in the Citi Biopharma Conference
Cogent Biosciences announced its participation in the Citi Biopharma Conference on September 3, 2025. The event will include a fireside chat and a live webcast available on the company's website. Additionally, Cogent disclosed the approval of inducement equity awards for new employees under its 2020 Inducement Plan, aimed at incentivizing talent acquisition.
Read more →COGT▼ -5.7%on this news
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis,
Cogent Biosciences announced positive top-line results from the SUMMIT trial for bezuclastinib in NonAdvanced Systemic Mastocytosis, achieving statistical significance across primary endpoints. The company reported a strong cash position of $453 million, allowing operations until 2027, and highlighted upcoming trial results from PEAK and APEX in the second half of 2025. Despite a growing net loss of $73.5 million in Q2 2025, Cogent's CEO expressed confidence in bezuclastinib's potential to become the standard-of-care.
Read more →COGTCogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Cogent Biosciences has successfully closed an upsized public offering of 25,555,556 shares at a price of $9.00 per share, generating gross proceeds of about $230 million. The funds will primarily be used for the development and commercialization of bezuclastinib, targeting genetically defined diseases. J.P. Morgan, Leerink Partners, and Guggenheim Securities acted as joint book-running managers for this offering. The transaction reflects significant investor confidence in Cogent's pipeline and future endeavors.
Read more →COGT▲ +6.3%on this newsshared move
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
Cogent Biosciences announced the pricing of its upsized public offering of 22,222,223 shares of common stock at $9.00 per share, aiming to raise around $200 million. The proceeds will fund the development and commercial preparation for bezuclastinib, a treatment for genetically defined diseases. The offering is scheduled to close on or about July 10, 2025. This move reflects a strong market interest in Cogent's precision therapy pipeline.
Read more →COGTCogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
Cogent Biosciences has announced a proposed public offering of $150 million in common stock, with an option for underwriters to purchase an additional $22.5 million. The proceeds from this offering will be used for ongoing development and commercial preparation activities related to their lead candidate, bezuclastinib. While the company aims to strengthen its capital position, the offering's final terms remain uncertain due to market conditions. The transaction is facilitated by several well-known financial institutions, enhancing its credibility in the market.
Read more →COGT▲ +23.4%on this news· ran to +43% by day 3shared move
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Masto
Cogent Biosciences announced positive top-line results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis. The trial achieved statistical significance across all primary and key secondary endpoints, demonstrating substantial improvements in patient-reported symptoms and reduction in mast cell burden. Cogent plans to submit a new drug application to the FDA by the end of 2025 and will present detailed results at an upcoming medical meeting. The results indicate a promising new treatment option for patients with significant unmet medical needs.
Read more →COGTCogent Biosciences Secures up to $400 Million in Non-Dilutive Financing Facility provides additional funding for next steps of the Company s growth, including the expected launch of bezuclastinib in 2026 On track to repo
Cogent Biosciences has announced the securing of a non-dilutive financing facility valued at up to $400 million to support its growth and the anticipated launch of its treatment bezuclastinib in 2026. An initial amount of $50 million has been drawn, with additional funding contingent on meeting specific clinical and commercial milestones. The company is also preparing to disclose results from three pivotal trials in 2025, starting with SUMMIT in July. This strategic financing aims to enhance Cogent's financial flexibility and facilitate the development of innovative therapies for genetically defined diseases.
Read more →COGT▲ +6.2%on this news· ran to +32% by day 3
Jefferies Global Healthcare Conference
Cogent Biosciences, Inc. presented its business operations and future plans at the Jefferies Global Healthcare Conference. The company focuses on several clinical candidates, particularly bezuclastinib, which has significant market potential. Upcoming results from clinical trials are expected in 2025, highlighting opportunities in gastrointestinal stromal tumors and systemic mastocytosis. However, the company faces risks linked to funding, regulatory approvals, and the success of its clinical trials.
Read more →COGT▼ -15.6%on this news
xfeff; Cogent Biosciences Reports First Quarter 2025 Financial Results Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected i
Cogent Biosciences announced its financial results for Q1 2025, revealing a net loss of $72 million. The company is preparing for three significant clinical data readouts in 2025, with SUMMIT results expected in July, alongside APEX and PEAK later in the year. Cogent ended the quarter with $245.7 million in cash, sufficient to fund its operations through late 2026. Despite financial losses and rising R&D expenses, critical data from ongoing trials may strongly influence the company's future prospects.
Read more →COGT▼ -15.6%on this news
Cogent Biosciences Reports First Quarter 2025 Financial Results
Cogent Biosciences has reported its financial results for the first quarter of 2025, highlighting their strategic focus on upcoming data readouts from pivotal clinical trials. The company boasts a cash position of $245.7 million, which is expected to sustain operations until late 2026. Positive early clinical results for bezuclastinib, particularly in improving Total Symptom Scores in patients, support the company's growth potential as they prepare for potential commercialization in 2026. However, they reported a net loss of $72 million for the quarter, indicating financial challenges amidst substantial R&D investments.
Read more →COGTCogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
Cogent Biosciences announced the presentation of four posters at the AACR 2025 Annual Meeting, showcasing preclinical data for its targeted therapies in cancer treatment. The company highlighted its promising KRAS and PI3K inhibitors, as well as an FGFR2/3 inhibitor in ongoing trials. Additionally, Cogent appointed new leaders to enhance its market access and corporate strategy. The findings contribute valuable insights into the company's drug development efforts aimed at rare disease populations with significant unmet medical needs.
Read more →COGT▼ -6.8%on this news
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Cogent Biosciences, Inc. has announced four preclinical poster presentations to be showcased at the 2025 American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025, in Chicago, IL. The presentations include an evaluation of a potent KRAS inhibitor and a novel PI3Kα inhibitor, among others. The company aims to address specific genetic mutations related to cancer through their innovative therapies. Additionally, Cogent has granted an equity award to a new employee as part of its 2020 Inducement Plan.
Read more →COGT▼ -5.4%on this news
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
Cogent Biosciences, Inc. has announced its participation in the upcoming Leerink Healthcare Conference scheduled for March 12, 2025. The company aims to showcase its developments in precision therapies for genetically defined diseases, notably through its advanced clinical program focusing on the KIT D816V mutation. Additionally, Cogent disclosed the approval of an inducement equity award aimed at attracting new talent to bolster its ongoing projects. A live webcast of the event will be available on their website.
Read more →COGTCogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Cogent Biosciences has revealed expanded clinical results from the Open Label Extension of their SUMMIT trial, focusing on the performance of bezuclastinib in patients with nonadvanced systemic mastocytosis. Results show a 65% mean improvement in Total Symptom Score over 48 weeks, with a significant majority of participants experiencing substantial symptom reductions. Patient-reported outcomes suggest notable improvements in quality of life, with results highlighting both the efficacy and safety of the treatment. Top-line results from SUMMIT Part 2 are set to be presented by July 2025.
Read more →COGT▼ -6.3%on this newsshared move
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 APEX trial enrollment in AdvSM pati
Cogent Biosciences has reported its financial results for Q4 and full year 2024, highlighting progress in pivotal trials for bezuclastinib in systemic mastocytosis. The company is on track to present top-line results from the SUMMIT trial by July 2025 and plans to submit its first NDA for bezuclastinib by the end of 2025. Despite a net loss of $255.9 million this year, Cogent maintains a robust cash position of $312 million, expected to support operations through late 2026. Recently reported positive clinical outcomes indicate a strong potential for the company's targeted therapies.
Read more →COGTCogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
Cogent Biosciences, Inc. has announced a poster presentation for its drug bezuclastinib at the upcoming 2025 AAAAI Annual Meeting. The focus will be on patients with NonAdvanced Systemic Mastocytosis who have been on 100mg bezuclastinib for at least 48 weeks, emphasizing the potential long-term benefits of the treatment. The presentation is scheduled for March 1, 2025, in San Diego, CA. Bezuclastinib is a targeted selective tyrosine kinase inhibitor designed to address specific mutations responsible for mast cell proliferation.
Read more →COGTCogent Biosciences to Participate in the Guggenheim Biotech Conference
Cogent Biosciences, Inc. announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference on February 5, 2025, where the company will engage in a fireside chat. The event reflects Cogent's proactive approach to investor relations as it discusses its focus on precision therapies. The company is best known for its treatment, bezuclastinib, which targets the KIT D816V mutation significant in systemic mastocytosis and advanced gastrointestinal stromal tumors. Additionally, Cogent is advancing its Phase 1 study of a novel FGFR2 inhibitor and developing other targeted therapies.
Read more →COGTCogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Cogent Biosciences has outlined its key milestones for 2025, emphasizing the reporting of top-line results from three major clinical trials involving its lead therapy, bezuclastinib. The company aims for a New Drug Application (NDA) submission by year-end if these trials are successful. Additionally, Cogent is expanding its portfolio with various ongoing studies and aims to enhance its presence in the biotechnology space. The company will present at the J.P. Morgan Healthcare Conference to discuss its advancements and future plans.
Read more →COGTCogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Cogent Biosciences, Inc. has announced that its President and CEO, Andrew Robbins, will present at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2025. This event emphasizes Cogent's ongoing efforts in the biotechnology sector, particularly in developing precision therapies for genetically defined diseases. Live webcasting of the presentation will be accessible on the company's investor page, with a replay available for later viewing. The company continues to advance its clinical program, bezuclastinib, aimed at specific genetic mutations associated with serious conditions.
Read more →COGT▲ +8.8%on this news
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Cogent Biosciences has reported promising updated clinical results from the SUMMIT trial, revealing a 56% mean improvement in Total Symptom Score among patients with nonadvanced systemic mastocytosis. Notably, 76% of patients experienced a significant reduction in symptoms, and 89% achieved a significant decrease in serum tryptase levels within four weeks. The company's enrollment in the subsequent part of the trial was completed earlier than expected, indicating strong interest and demand for the treatment. Top-line results from this segment of the trial are anticipated in July 2025.
Read more →COGT▲ +8.8%on this newsshared move
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences announced encouraging results from Part 1 of its Phase 2 APEX trial for bezuclastinib in advanced systemic mastocytosis (AdvSM). The trial exhibited a 52% overall response rate (ORR) per mIWG criteria, with 83% ORR for patients treated with 100 mg BID. The median time to response was recorded at 2.2 months, with safety data showing a favorable profile. Cogent plans to continue enrollment in Part 2, with top-line data expected in mid-2025.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results Top-line results from registration-directed SUMMIT, PEAK and APEX trials expected in 2025 Phase 1 trial initiated for CGT-485
Cogent Biosciences has reported positive advancements in its clinical pipeline and strong financial results for the third quarter of 2024. The company is preparing to deliver top-line results from the SUMMIT, PEAK, and APEX trials in 2025, following the completion of patient enrollment in the PEAK trial. Cogent's strong cash position of $346 million allows for continued operational funding into late 2026, although it reported a net loss of $70.6 million this quarter, an increase from the previous year. The company also initiated a Phase 1 trial for CGT-4859, which is a selective FGFR2 inhibitor.
Read more →COGT▼ -15.8%on this news
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
Cogent Biosciences announced two presentations featuring bezuclastinib at the upcoming 66th Annual Meeting of the ASH. These presentations will include long-term follow-up data from the APEX and SUMMIT trials, which evaluate bezuclastinib's safety and efficacy in patients with systemic mastocytosis. The event will take place from December 7-10, 2024, in San Diego, California, featuring participation from key leaders in the field. Additionally, Cogent will host a webcast reviewing the presentation data on December 9, 2024.
Read more →COGTCogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Cogent Biosciences has revealed the expansion of its pipeline to include a potent KRAS inhibitor and presented updated preclinical findings on CGT6297, a selective PI3Kα inhibitor, at the 2024 EORTC-NCI-AACR symposium in Barcelona. The new programs demonstrate strong efficacy with promising pharmacological attributes, hinting at their potential as best-in-class therapies. The company emphasizes its commitment to developing targeted therapies tailored for genetically defined diseases. CGT6297 aims to address challenges faced by existing treatments while maintaining higher efficacy and lower dose limitations.
Read more →COGTCogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis 413 patients enrolled in PEAK Phase 3 GIST tria
Cogent Biosciences has completed patient enrollment in its Phase 3 PEAK trial for gastrointestinal stromal tumors (GIST), enrolling 413 patients, surpassing its target. An interim futility analysis indicated that the trial should proceed without modifications. Top-line results from the trial are anticipated by the end of 2025. Additionally, the SUMMIT trial for nonadvanced systemic mastocytosis is on track to complete enrollment in Q1 2025.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all th
Cogent Biosciences reported strong progress in its clinical trials during the second quarter of 2024, with enrollment for its SUMMIT, PEAK, and APEX studies on track and topline results expected in 2025. The company ended the quarter with a solid cash position of $390 million, which will fund operations until 2027. Positive clinical data for its lead product, bezuclastinib, was highlighted, showing significant symptom reduction in patients. However, the company also reported an increased net loss of $59 million for the quarter, reflecting higher research and development costs.
Read more →COGTCogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial Enrollment in SUMMIT Part 2 remains on track for completion in Q2 2025 with top-line
Cogent Biosciences announced a positive meeting with the FDA regarding its novel patient-reported outcome measure, MS2D2, for the SUMMIT trial. Enrollment in Part 2 of the SUMMIT trial, which evaluates the efficacy of bezuclastinib in Nonadvanced Systemic Mastocytosis patients, is expected to be completed by Q2 2025, with top-line results anticipated by the end of 2025. The company is also advancing other clinical trials, including the APEX study for Advanced Systemic Mastocytosis and the PEAK study for gastrointestinal stromal tumors, both of which are on track for timely completion.
Read more →COGT▼ -6.2%on this news
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences has announced additional encouraging clinical data from Part 1 of its SUMMIT trial assessing the efficacy of bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM). Patients treated with 100 mg of the drug exhibited significant reductions in severe symptoms and mast cell reactions. The results indicate positive objective measures of disease, including improvements in skin lesions. The company aims to complete enrollment for Part 2 of the trial by Q2 2025, with topline results expected by the end of 2025.
Read more →COGT▼ -6.7%on this news
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
Cogent Biosciences announced positive updated lead-in data from its ongoing Phase 3 PEAK trial evaluating the combination of bezuclastinib and sunitinib in patients with gastrointestinal stromal tumors (GIST). The median progression-free survival reported was 19.4 months for a specific patient subset, along with encouraging safety data. Additionally, enrollment for the trial is expected to complete in the third quarter of 2024. The company also revealed plans for a new Phase 2 clinical trial for later line GIST patients in collaboration with SARC and Dana-Farber Cancer Institute.
Read more →COGT▼ -6.7%on this news
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
Cogent Biosciences has appointed Cole Pinnow as Chief Commercial Officer, aiming to strengthen its commercial strategies ahead of the anticipated launch of bezuclastinib for systemic mastocytosis and gastrointestinal stromal tumors. Pinnow brings 25 years of commercial experience, previously leading teams at Pfizer. His primary role will include building a capable commercial team to support Cogent's transition from research to a fully-integrated commercial organization. The appointment signifies Cogent's commitment to addressing unmet medical needs in targeted therapies.
Read more →COGTCogent Biosciences Reports First Quarter 2024 Financial Results SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 202
Cogent Biosciences announced its financial results for the first quarter of 2024, indicating strong progress in its clinical trials, including SUMMIT, PEAK, and APEX. The company reported a cash position of $435.7 million, providing a solid runway into 2027 to support ongoing operations and trial enrollments. Notably, positive trial data on bezuclastinib's effectiveness in treating systemic mastocytosis was presented, with topline results from all studies expected in 2025. However, Cogent also reported a net loss of $58.3 million, raising concerns about its growing expenses amidst rapid trial developments.
Read more →COGT▲ +7.2%on this news
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
Cogent Biosciences has presented new preclinical data for its ErbB2 inhibitor at the AACR 2024 Annual Meeting. This data suggests the compound may have best-in-class potential due to its selectivity and ability to penetrate the CNS effectively. The company plans to begin IND-enabling studies for this promising candidate in mid-2024, targeting rare diseases that currently lack effective treatments. The findings further emphasize Cogent's commitment to developing innovative therapies for genetically defined conditions.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results SUMMIT Part 2 registration-directed study of bezuclastinb in NonAdvSM patients initiated and actively enrollin
Cogent Biosciences has initiated the SUMMIT Part 2 study for bezuclastinib targeting NonAdvSM patients, with active enrollment at 40 global sites. Concurrently, the PEAK Phase 3 trial for bezuclastinib in 2nd-line GIST patients is on track for enrollment completion by the end of 2024. The company reported a strong financial position with $487 million in pro-forma cash, enough to fund operations until 2027. Expectation for topline results from multiple trials is set for 2025, highlighting the potential of bezuclastinib in treating specific genetic disorders.
Read more →COGTCogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Cogent Biosciences reported positive results from Part 1b of the SUMMIT trial for bezuclastinib in nonadvanced systemic mastocytosis patients, showing a 51% mean reduction in Total Symptom Score at week 12. The company also announced the initiation of Part 2 of the trial, which aims to support registration under an optimized 100 mg daily dose. Overall, bezuclastinib demonstrated a favorable safety profile with no severe adverse events reported. Cogent aims to establish bezuclastinib as a leading treatment option for systemic mastocytosis.
Read more →COGT▲ +59.3%on this news
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMM
Cogent Biosciences announced a successful $225 million oversubscribed private placement, which will fund their operations and trials into 2027. The financing is expected to support their ongoing registration-directed trials of bezuclastinib for treating systemic mastocytosis and gastrointestinal stromal tumors. The company will utilize the funds for research, development, and general corporate purposes. Furthermore, they plan to provide an update on the SUMMIT Part 1b clinical trial data during an upcoming investor webcast.
Read more →COGT▲ +18.8%on this news· ran to +33% by day 3
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
Cogent Biosciences, Inc. announced its participation in the 2024 AAAAI Annual Meeting, where it will present initial results from the SUMMIT Part 1b clinical study focusing on bezuclastinib for NonAdvanced Systemic Mastocytosis. The presentations will take place on February 25, 2024, at the Walter E. Washington Convention Center in Washington, D.C. Additionally, a virtual investor webcast will be held on February 23, 2024, providing insights into the study's findings. Bezuclastinib is a targeted therapy aimed at specific genetic mutations linked to mast cell disorders.
Read more →COGT▼ -7.7%on this news
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Cogent Biosciences has outlined ambitious milestones for 2024, including the commencement of a pivotal trial for bezuclastinib in NonAdvSM patients and the expected completion of enrollment in ongoing studies for advanced systemic mastocytosis and gastrointestinal stromal tumors. The company also aims to initiate a Phase 1 trial for CGT4859, a novel FGFR2 inhibitor. Cogent's leadership is optimistic about their financial position, with enough capital to support operations into 2026, and they plan to present key data at the upcoming AAAAI conference.
Read more →COGT▲ +6.1%on this news
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Cogent Biosciences, Inc. has announced that its CEO, Andrew Robbins, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will be part of Cogent's efforts to showcase its advancements in developing precision therapies for genetically defined diseases. Cogent's lead program, bezuclastinib, targets the KIT D816V mutation linked to systemic mastocytosis and also addresses other mutation-related cancers. Interested investors can access a live webcast of the event on Cogent's website.
Read more →COGT▼ -53%on this news
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences has announced positive initial results from Part 1 of the Phase 2 APEX trial evaluating bezuclastinib for patients with advanced systemic mastocytosis (AdvSM). The trial reported a 56% overall response rate in TKI-naïve patients, alongside significant reductions in key disease biomarkers. Additionally, the treatment demonstrated an encouraging safety profile, with minimal serious adverse events. Cogent aims to complete enrollment for Part 2 of the trial by the end of 2024, with high hopes for its efficacy as a new treatment option.
Read more →COGT▼ -53%on this newsshared move
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences has released positive initial data from its Phase 2 SUMMIT trial of bezuclastinib for treating nonadvanced systemic mastocytosis (NonAdvSM). The trial showed significant improvements in patient-reported outcomes, with 57% achieving a median best improvement on quality of life measures. Additionally, all patients treated with bezuclastinib demonstrated over 50% reductions in various biomarkers related to the disease. The study reports a favorable safety profile, emphasizing the potential for chronic treatment.
Read more →COGTCogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
Cogent Biosciences, Inc. will host a webcast on December 11, 2023, to discuss clinical data from its SUMMIT and APEX studies on systemic mastocytosis. The webcast will follow presentations at the American Society of Hematology Annual Meeting, with initial data from SUMMIT being presented on December 9 and further updates from APEX on December 11. The event will feature key presentations from company executives and leading medical professionals, highlighting the company’s dedication to developing targeted therapies for genetically defined diseases.
Read more →COGT▲ +5.7%on this news· ran to +17% by day 3shared move
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
Cogent Biosciences, Inc. has announced two poster presentations at the upcoming 2023 San Antonio Breast Cancer Symposium, scheduled for December 5-9, 2023. The presentations will showcase research on a novel EGFR sparing inhibitor and a PI3Kα mutant-selective inhibitor. These developments underline the company's focus on precision therapies for genetically defined diseases, specifically targeting oncogenic mutations relevant to breast cancer treatment.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSM data selected for oral presentati
Cogent Biosciences has reported its third quarter 2023 financial results, highlighting progress in its SUMMIT and APEX clinical trials. The company ended the quarter with $312.8 million in cash, projecting sufficient funding into 2026. The updates include a 33% overall response rate for the drug bezuclastinib in second-line GIST patients and planned oral presentations at the upcoming ASH Annual Meeting. Future research efforts are on track with significant clinical trial milestones approaching.
Read more →COGTCogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Cogent Biosciences has presented promising preclinical data on its next-generation selective FGFR2 inhibitor, CGT4859, which shows strong potency against various mutations. The company plans to file an Investigational New Drug (IND) application and initiate clinical trials in the second half of 2024. The new inhibitor aims to provide improved tolerability compared to existing treatments, addressing limitations like FGFR1-mediated toxicity. These updates were shared at the 2023 AACR-NCI-EORTC conference in Boston.
Read more →COGT▲ +7.6%on this news
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on t
Cogent Biosciences has reported its second quarter 2023 financial results, highlighting significant clinical progress and a strong cash position. The company presented positive lead-in data from the Phase 3 PEAK trial, showing promise for bezuclastinib in treating GIST. Cogent also announced its selection of a new FGFR2 inhibitor as a clinical candidate. Despite a reported net loss of $44.1 million, the company has sufficient funds to operate into 2026.
Read more →COGTCogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
Cogent Biosciences has successfully closed its upsized public offering of 12.5 million shares at a price of $12 each, raising approximately $150 million. The company plans to utilize the proceeds for development and regulatory activities related to its lead product, bezuclastinib, alongside other initiatives and general corporate purposes. This offering engaged multiple financial partners including J.P. Morgan and Jefferies, showcasing significant market confidence in Cogent’s business trajectory.
Read more →COGT▼ -10.2%on this newsshared move
Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference
Cogent Biosciences, Inc. has announced its participation in a fireside chat at the Jefferies Healthcare Conference set for June 8, 2023. The event will be held at 9:30 a.m. ET in New York, with a live webcast accessible via the company's website. Cogent focuses on precision therapies for genetically defined diseases, notably highlighting its clinical program for bezuclastinib, a selective tyrosine kinase inhibitor targeting specific mutations. The company's participation in this conference underscores its commitment to open communication with investors.
Read more →COGTCogent Biosciences Announces Proposed Public Offering of Common Stock
Cogent Biosciences has announced a proposed public offering of $125 million in common stock to support the development of its precision therapies. The proceeds will primarily be used for regulatory activities related to bezuclastinib and for general corporate purposes. Additionally, the company has granted underwriters a 30-day option to purchase an extra $18.75 million worth of shares. The offering is being managed by several financial institutions and will be conducted under an automatic shelf registration statement filed with the SEC.
Read more →COGTCogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences has announced positive lead-in data from its ongoing Phase 3 PEAK trial evaluating the combination of bezuclastinib and sunitinib in patients with gastrointestinal stromal tumors (GIST). The trial revealed a 55% disease control rate and a 100% disease control rate among efficacy-evaluable second-line patients. The combination therapy demonstrated a well-tolerated safety profile consistent with sunitinib alone, suggesting potential as a new treatment standard for imatinib-resistant GIST patients. However, the data is preliminary, and progression-free survival metrics remain immature.
Read more →COGTCogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences, Inc. announced an investor webcast to discuss lead-in data from its ongoing Phase 3 PEAK trial. This trial evaluates bezuclastinib combined with sunitinib for patients with gastrointestinal stromal tumors (GIST). The data will also be presented at the upcoming ASCO Annual Meeting. The webcast is scheduled for June 5, 2023, and aims to provide insights into the trial's findings and the company's future developments.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Cogent Biosciences has released its business update and financial results for Q1 2023, highlighting key clinical trial advancements and a strong cash position. The company is set to present lead-in data from its Phase 3 PEAK trial at the ASCO Annual Meeting. With multiple ongoing clinical trials and favorable regulatory designations, Cogent is focused on developing therapies for genetically defined diseases. However, the company reported increased net losses and rising R&D expenses during the quarter.
Read more →COGT▲ +6.6%on this news
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations In vivo characterization shows a novel, selective, reversible FGFR2 inhibitor has potency against molecular brake mutations and potential advantages over
Read more →COGT▼ -5.7%on this newsshared move
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual i
Read more →COGT▲ +7.5%on this news
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results Initiation of APEX Part 2 planned for mid-2023 Updated clinical data from Phase 3 PEAK lead-in in GIST patient
Cogent Biosciences has updated its stakeholders on business highlights and financial results for 2022. The company plans to initiate APEX Part 2 trials in mid-2023 and expects to present updated clinical data from the Phase 3 PEAK trial in the first half of 2023. They concluded 2022 with $259.3 million in cash, which is projected to support operations until 2025. Cogent's promising clinical data for its lead drug, bezuclastinib, has set a positive outlook for the upcoming year, while the company grapples with significant operational losses.
Read more →COGTCogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from Phase 2 SUMMIT trial in NonAdvSM patients Rapidly progress bezuclastinib in 2nd-li
Read more →COGTCogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Off
Read more →COGT▲ +9%on this news
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) 89% ORR in TKI-therapy na ve patients; 73% ORR
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) 89% ORR in TKI-therapy na ve patients; 73% ORR in all evaluable patients with 27-week median follow-up Rapid and deep res
Read more →COGTCogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Mond
Read more →COGTCogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice Pre
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic
Read more →COGTCogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming presentations for bezuclastinib at the 64th A
Read more →COGTCogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results On-track to present additional data from Phase 2 APEX trial by the end of 2022 Initial data from Phase 2 SUMMIT trial & lead
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results On-track to present additional data from Phase 2 APEX trial by the end of 2022 Initial data from Phase 2 SUMMIT trial & lead-in data from Phase 3 PEAK trial planned for 1H23 Ended
Read more →COGT▼ -6.5%on this news
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters Option to Purchase Additional Shares CAMBRIDGE, Mass. and
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters Option to Purchase Additional Shares CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechn
Read more →COGTCogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants
CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 15
Read more →COGT▲ +58.7%on this news· ran to +76% by day 1shared move
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) All patients treated with bezuclastinib achieve
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) All patients treated with bezuclastinib achieved 50% reduction in serum tryptase, with a median reductio
Read more →COGTCogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it will host an investor webcast on Friday, June 10,
Read more →COGTCogent Biosciences Announces Annual Meeting of Stockholders
CAMBRIDGE, Mass. and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the Annual Meeting of Stockholders will take place v
Read more →COGT▼ -7.1%on this news
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced a poster presentation at the European Hematology Asso
Read more →COGT▼ -8.3%on this news· ran to -27% by day 3shared move
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential
Read more →COGTCogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat a
Read more →COGTCogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors Building a pipeline of multiple small molecule inhibitors targeting genetically defined diseases, includi
Read more →COGT▲ +5.8%on this news
Cogent Biosciences to Host Virtual R&D Investor Event
CAMBRIDGE, Mass. and BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced details for its planned Virtual R&D Investor Event
Read more →COGTCogent Biosciences Provides Corporate Updates , Fourth Quarter and Full Year 2021 Financial Results APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event pla
Read more →COGTCogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022
CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the publication of two abstracts for its upcoming p
Read more →COGTCogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and Presiden
Read more →COGTCogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results Initiated SUMMIT, a Phase 2 clinical trial of bezuclastinib for Nonadvanced Systemic Mastocytosis (NonAdvSM) patients PEAK, a
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results Initiated SUMMIT, a Phase 2 clinical trial of bezuclastinib for Nonadvanced Systemic Mastocytosis (NonAdvSM) patients PEAK, a Phase 3 clinical trial of bezuclastinib and sunitinib fo
Read more →COGTCogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results Initiated Phase 2 open-label clinical study (APEX) for bezuclastinib (CGT9486) in patients with Advanced Systemic Mastocytos
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results Initiated Phase 2 open-label clinical study (APEX) for bezuclastinib (CGT9486) in patients with Advanced Systemic Mastocytosis (AdvSM) SUMMIT study for patients with Non-Advanced Sy
Read more →COGTCogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John R
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lea
Read more →COGTCogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results CGT9486 clinical trial initiations on-track: Advanced Systemic Mastocytosis (1H21), Non-Advanced Systemic Mastocytosis (2H21), Gastroint
Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results CGT9486 clinical trial initiations on-track: Advanced Systemic Mastocytosis (1H21), Non-Advanced Systemic Mastocytosis (2H21), Gastrointestinal Stromal Tumors (GIST) (2H21) data from CGT9486 +
Read more →COGTDeveloping Precision therapies for genetically defined diseases Corporate Presentation Q4 2020 Forward Looking Statements and Risk Factors This presentation and the accompanying oral commentary contain forward-looking st
therapies for genetically defined diseases Corporate Presentation Q4 2020Exhibit 99.1 Developing Precision therapies for genetically defined diseases Corporate Presentation Q4 2020 Forward Looking Statements and Risk Factors This presentation and the accompanying oral commentar
Read more →COGTCogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates Andrew Robbins appointed President, CEO and Director Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients
Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates Andrew Robbins appointed President, CEO and Director Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients selected for oral presentation at Connective Tissue Oncol
Read more →COGTCogent Biosciences Appoints Andrew Robbins as Chief Executive Officer Seasoned executive with deep experience developing precision medicines for genetically defined diseases, most recently as COO of Array Biopharma CAMBR
Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer Seasoned executive with deep experience developing precision medicines for genetically defined diseases, most recently as COO of Array Biopharma CAMBRIDGE, MASS., October 26, 2020 Cogent Biosciences, Inc. (
Read more →COGTUnum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the live
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into Sy
Read more →COGTUnum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO Transaction focused on the BOXR technology including lead program BOXR1030 Company fully focused on the development of small molecule precision kina
Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO Transaction focused on the BOXR technology including lead program BOXR1030 Company fully focused on the development of small molecule precision kinase inhibitors to treat a range of genetically driven disea
Read more →COGTUnum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates Completed acquisition of Kiq, including lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor Comp
Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates Completed acquisition of Kiq, including lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor Company positioned to advance best-in-class precision kinase
Read more →COGTUnum Therapeutics Inc. Announces Acquisition of Kiq LLC Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor Company positioned to advance best-in-class precision kinase i
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor Company positioned to advance best-in-class precision kinase Proceeds of $104.4 million to be used to advance clinical
Read more →COGTUnum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates CAMBRIDGE, MA
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates CAMBRIDGE, MA, May 11, 2020 Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial resu
Read more →COGTUnum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates CAMBRIDGE, MA
Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates CAMBRIDGE, MA, March 26, 2020 Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today an
Read more →COGTUnum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital CAMBRIDGE, MA
Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital CAMBRIDGE, MA, March 20, 2020 Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today an
Read more →COGTUnum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers -BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to i
Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers -BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironmen
Read more →COGTUnum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers -Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety a
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ -Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety and efficacy data from multiple dose cohorts expected during 2020- CAMBRIDGE,
Read more →COGTForward-Looking Statements and Risk Factors This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever
Corporate presentation JANUARY 2020 Forward-Looking Statements and Risk Factors This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the ass
Read more →COGTUnum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting -Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Pha
Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting -Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL-
Read more →COGTUnum Therapeutics Reports Third Quarter 2019 Financial Results - Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected
Unum Therapeutics Reports Third Quarter 2019 Financial Results - Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year- CAMBRIDGE, MA, November 12, 201
Read more →COGTUnum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting - Unum s first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell f
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting - Unum s first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell functionality in the solid tumor microenvironment - - BOX
Read more →COGTUnum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers - Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum s goals
Unum Therapeutics Announces Strategic Focus on Developing Cellular Therapies for Solid Tumor - Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum s goals are to more selectively target solid tumors with its ACTR platform candidates
Read more →COGTUnum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates - Updated results from Phase 1 trial with ACTR707 in combination with rituximab in adults with relapsed/refractory non-Hodgki
Unum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates - Updated results from Phase 1 trial with ACTR707 in combination with rituximab in adults with relapsed/refractory non-Hodgkin lymphoma confirms the clinical activity achieved in pr
Read more →COGTUnum Therapeutics Announces New Appointments to its Board of Directors
Unum Therapeutics Announces New Appointments to its Board of Directors CAMBRIDGE, Mass., July 29, 2019 (GLOBE NEWSWIRE) Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based
Read more →COGTUnum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087
Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087 CAMBRIDGE, Mass., July 2, 2019 (GLOBE NEWSWIRE) Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer
Read more →COGTUnum Therapeutics Strengthens and Expands Leadership Team Matthew Osborne Appointed as Chief Financial Officer Jessica Sachs Promoted to Chief Medical Officer Mert Aktar Appointed as Head of Business and Corporate Develo
Unum Therapeutics Strengthens and Expands Leadership Team Matthew Osborne Appointed as Chief Financial Officer Jessica Sachs Promoted to Chief Medical Officer Mert Aktar Appointed as Head of Business and Corporate Development CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) U
Read more →COGTUnum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update - Advancing ACTR Clinical Programs in Non-Hodgkin Lymphoma, Multiple Myeloma, and HER2+ Advanced Cancers Through Dose Escalation
Unum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update - Advancing ACTR Clinical Programs in Non-Hodgkin Lymphoma, Multiple Myeloma, and HER2+ Advanced Cancers Through Dose Escalation Studies with Data Expected from All Four Ongoing Trials
Read more →COGTUnum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update - Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update - Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued Dose Escalation of ATTCK-17-01 Trial
Read more →COGTUNUM THERAPEUTICS CORPORATE PRESENTATION TH COWEN AND COMPANY 39 ANNUAL HEALTHCARE CONFERENCE BOSTON, MA MARCH 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary conta
COMPANY 39 ANNUAL HEALTHCARE CONFERENCE BOSTON, MA MARCH 2019Exhibit 99.1 UNUM THERAPEUTICS CORPORATE PRESENTATION TH COWEN AND COMPANY 39 ANNUAL HEALTHCARE CONFERENCE BOSTON, MA MARCH 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral
Read more →COGTUnum Therapeutics Announces Transition of Chief Financial Officer CAMBRIDGE, MA
Unum Therapeutics Announces Transition of Chief Financial Officer CAMBRIDGE, MA, January 3, 2018 Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced that Christiana Stamo
Read more →COGTUnum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 ASH Annual Meeting CAMBRIDGE, MA
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 CAMBRIDGE, MA, December 1, 2018 Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing Phase 1 ATTCK-17-01 study, testing ACTR087 in combinatio
Read more →COGTUnum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update - ACTR707 in Combination with Rituximab Selected as Lead Product Candidate for Further Development in r/r NHL - New Solid Tumors
Unum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update - ACTR707 in Combination with Rituximab Selected as Lead Product Candidate for Further Development in r/r NHL - New Solid Tumors Technology Platform Revealed at SITC - More Details on S
Read more →COGTUnum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update IND for First Solid Tumor Program, ACTR T cells in Combination with Trastuzumab in Patients with HER2+ Advanced Cancers Now Act
Unum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update IND for First Solid Tumor Program, ACTR T cells in Combination with Trastuzumab in Patients with HER2+ Advanced Cancers Now Active; Expect to Initiate Phase I Trial by End of 2018 CAMB
Read more →COGTUnum Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update Successfully Completed IPO and Concurrent Private Placement Raising $77 Million in Gross Proceeds Initiated Cohort Expansion of
Unum Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update Successfully Completed IPO and Concurrent Private Placement Raising $77 Million in Gross Proceeds Initiated Cohort Expansion of ATTCK-20-2 Phase I Trial of ACTR087 in Combination with R
Read more →Competitive Position
How COGT ranks across every disease it competes inCompetitive Position is a premium feature
See how COGT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial